IL2 and cancer: Although IL-2-mediated cancer immunotherapy has been used in the clinic for many years, high dose IL‐2 promotes the proliferation of cytotoxic effector T cells, as well as Treg cells, which can suppress the activity of effector T cells and thereby limit their antitumor efficacy (30, 31).